Delivery Order SPE2DB20D1004-SPE2DB21FG1B1
Award Date
9/21/21
Potential Completion Date
9/22/21
Potential Value
$14K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999.00 through December 2026. The contract is for the delivery of Pulmozyme, a medication used to treat cystic fibrosis, with a ceiling value of $75,527.66. The contract is a firm fixed-price arrangement and does not have a set-aside designation,...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $78,888.63 delivery order is for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml) under a Firm Fixed Price contract type. The award is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026....
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $14,881.52, is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a pharmaceutical product. This is a firm fixed-price delivery order contract with an ultimate completion date of May 22, 2023. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/ml ampuls. The contract, valued at $32,686.58, is a firm-fixed-price delivery order with an ultimate completion date of January 19, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order worth $18,985.48 for the supply of Pulmozyme 1 mg/ml ampuls. The contract is with the Defense Logistics Agency Troop Support Medical and has an ultimate completion date of May 22, 2023. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00, which serves as the primary vehicle for delivering a...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order contract valued at $34,765.30. The contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $60,373.02 firm-fixed-price delivery order is for the supply of Pulmozyme 1 mg/ml ampul, 2.5 ml, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of March 13, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also does...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,352.80, is for the delivery of Pulmozyme 1 mg/mL ampuls, a medication used to treat cystic fibrosis. The contract is a Firm Fixed Price Delivery Order with a completion date of February 11, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999...
This contract award, valued at $34,586.02, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a specialty pharmaceutical product. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for...
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,221.96 firm fixed-price delivery order contract is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used to treat cystic fibrosis. The contract has an ultimate completion date of June 11, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...